N@N

Market Maker Surveillance Report. XLF, EEM, EWT, EWJ, MYL, ORCL, Bearishly Biased Price Friction For Monday, May 16th 2011

^{Published on 2011-05-16 17:50:43 - WOPRAI}
 

May 16, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 2454 companies with "abnormal" market making, 1420 companies with positive Friction Factors and 3791 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. FINANCIAL SELECT SECTOR SPDR (NYSE:XLF), ISHARES MSCI EMERGING MKT IN (NYSE:EEM), ISHARES MSCI TAIWAN INDEX FD (NYSE:EWT), ISHARES MSCI JAPAN INDEX FD (NYSE:EWJ), MYLAN INC (NASDAQ:MYL), ORACLE CORP (NASDAQ:ORCL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     XLF        $-0.030      -0.19%       20,535,550      28.22%       16,512,520      22.69%       4,023,030       Abnormal
     EEM        $-0.170      -0.36%       21,702,659      29.56%       19,088,407      26.00%       2,614,252       Abnormal
     EWT        $-0.120      -0.77%       6,000,839       44.97%       3,663,409       27.45%       2,337,430       Abnormal
     EWJ        $-0.060      -0.59%       15,008,657      38.63%       8,464,246       21.79%       6,544,411       Abnormal
     MYL        $-0.300      -1.25%       4,403,505       71.23%       1,774,876       28.71%       2,628,629       Abnormal
     ORCL       $-1.010      -2.87%       16,349,505      53.74%       13,686,613      44.99%       2,662,892       Abnormal

For example, the chart above shows XLF with 4,023,030 greater shares of buying than selling (NetVol) and the stock price was down $-0.03000. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more buying than selling should cause prices to rise.

FINANCIAL SELECT SECTOR SPDR (NYSE:XLF) - FINANCIAL SEL SPD

ISHARES MSCI EMERGING MKT IN (NYSE:EEM) - ISHARES MSCI E.M.

ISHARES MSCI TAIWAN INDEX FD (NYSE:EWT) - ISHARES MSCI TAIWAN

ISHARES MSCI JAPAN INDEX FD (NYSE:EWJ) - ISHARE MSCI JAPAN

MYLAN INC (NASDAQ:MYL) - Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment offers generic or branded generic pharmaceutical products in tablet, capsule, or transdermal patch form, as well as APIs. This segment markets its products for the proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies located primarily in the United States and Canada, Europe, the Middle East, Africa, Australia, Japan, India, and New Zealand. The Specialty segment provides branded specialty nebulized, injectable, and transdermal products for life-threatening conditions. Its principal products comprise EpiPen that is used for the treatment of severe allergies; and Perforomist Inhalation Solution, a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease patients. This segment markets its products to the pharmaceutical wholesalers and distributors located primarily in the United States. Additionally, Mylan manufactures and supplies APIs for the manufacture of anti-retroviral (ARV) drugs, which are utilized in the treatment of HIV/AIDS; and offers a line of finished dosage form (FDF) products in both the ARV and non-ARV markets. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan was founded in 1961 and is based in Canonsburg, Pennsylvania.

ORACLE CORP (NASDAQ:ORCL) - Oracle Corporation, an enterprise software company, develops, manufactures, markets, distributes, and services database and middleware software, applications software, and hardware systems worldwide. It engages in licensing database and middleware software, including database, application server and application grid, SOA suite and business process management, data migration and integration, business intelligence, identity and access management, content management, portal and user interaction, developer tools, Oracle enterprise manager, and Java platform. The company also offers application software, including enterprise resource planning, customer relationship management, enterprise performance management, supply chain management, business intelligence applications, enterprise project portfolio management, and industry-specific applications; and software license updates and product support services. In addition, it provides hardware systems products, such as servers, storage products, Solaris operating system and other hardware-related software, and networking components and products; and hardware systems support services. Further, the company offers consulting services, which include enterprise architecture design and implementation, business/IT strategy alignment, business process simplification, solution integration, and product implementation, enhancements, and upgrades; on demand and advanced customer services; and training services, as well as certification programs. It markets and sells its products directly, as well as through resellers, system integrators/implementers, consultants, education providers, Internet service providers, network integrators, and independent software vendors to various industries, government agencies, and educational institutions. The company has a strategic alliance with Cap Gemini S.A. to market and implement Oracle Revenue Management for public. Oracle was founded in 1977 and is headquartered in Redwood City, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net